TICKERNERD
Menu
IBRXIBRXHealthcare · Biotechnology

IBRX Stock Forecast: ImmunityBio, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$7.57
−1.05% on the day

The 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $12 — +58.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 14 Aug 2026 — in the lower half.

Market cap
$8.2B
Ticker Nerd rank
48 / 100
Median analyst target
$12
Analysts covering
4
Total return, dividends reinvested
1W
−0.9%
1M
−3.9%
YTD
+282.3%
1Y
+179.3%
From 52W high
−34.5%
From 52W low
+282.3%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
90
Accruals
89
Momentum
76
Revisions
52
Quality
46
Growth
44
Volatility
25
Size
18
Issuance
6

Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26IBRXHigh $15Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $12High $15

The green dot is the last close — the median target sits +58.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2026HC Wainwright & Co.ReiteratesBuy$15
21 May 2026BTIGReiteratesBuy—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
12 Mar 2026BTIGAssumesBuy$13
9 Mar 2026D. Boral CapitalMaintainsBuy—
4 Mar 2026Piper SandlerReiteratesOverweight—
23 Feb 2026D. Boral CapitalMaintainsBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026D. Boral CapitalMaintainsBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026BTIGMaintainsBuy—
23 Jan 2026D. Boral CapitalMaintainsBuy—
20 Jan 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

ImmunityBio, Inc. (IBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−20.6×

Cheaper than 96% of US stocks

Price / sales
50.4×

Cheaper than 6% of US stocks

Price / book
−7.9×

Cheaper than 97% of US stocks

EV / EBITDA
−38.6×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
93.9%

Higher than 93% of US stocks

Earnings growth (YoY)
93.9%

Higher than 84% of US stocks

Gross margin
99.4%

Higher than 99% of US stocks

Operating margin
−120.4%

Higher than 13% of US stocks

Net margin
99.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
70.3%

Higher than 94% of US stocks

Return on assets
−30.5%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBRXImmunityBio, Inc.$8.2B
48
RYTMRhythm Pharmaceuticals, Inc.$8.0B
88
TGTXTG Therapeutics, Inc.$7.7B
65
PCVXVaxcyte, Inc.$8.2B
49
IMVTImmunovant, Inc.$8.4B
40
ORKAOruka Therapeutics, Inc.$7.4B
41
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBRX news & analysis

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

Business Wire · 10 Aug 2026positive

ImmunityBio has appointed Dr. Jim Yong Kim, former President of the World Bank and a global health leader, as Vice Chairman. He will serve in a newly created Office of the Executive Chairman, focusing on strengthening the company's international and global relationships.

Why it matters — This appointment brings a prominent global health and leadership figure to ImmunityBio's executive team, which could enhance the company's international partnerships and credibility.

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

Zacks Investment Research · 5 Aug 2026positive

ImmunityBio beat Q2 earnings and revenue estimates, with record Anktiva sales and continued adoption fueling growth. The company has additional regulatory milestones ahead.

Why it matters — The earnings and revenue beat, driven by record Anktiva sales and adoption, signals strong commercial momentum and may focus watchers on upcoming regulatory milestones.

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 4 Aug 2026positive

ImmunityBio reported a Q2 loss of $0.08 per share, beating the Zacks Consensus Estimate of a $0.09 loss and narrowing from a $0.10 per-share loss a year ago.

Why it matters — The narrower-than-expected loss signals improved financial performance, which IBRX watchers would view as a positive earnings surprise.

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

Business Wire · 4 Aug 2026positive

ImmunityBio reported financial and operational results for Q2 2026, with net product revenue reaching $50.7 million, up 92% year-over-year and 15% sequentially. First-half revenue rose 121% to $94.8 million, and the company said it advanced multiple regulatory and clinical programs across its immunotherapy pipeline.

Why it matters — An IBRX watcher would care because the company posted record product revenue growth while continuing to advance its immunotherapy pipeline across regulatory and clinical programs.

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

Benzinga · 30 July 2026positive

The Emirates Drug Establishment in the United Arab Emirates approved ImmunityBio's immunotherapy drug, ANKTIVA. The company described the move as the world's broadest bladder cancer approval.

Why it matters — The UAE approval expands ANKTIVA's regulatory reach into a new international market, broadening the drug's commercial footprint beyond the U.S.

FAQ

Frequently asked questions about IBRX stock

What is the IBRX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBRX stock a buy right now?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 48 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBRX?

As at 14 Aug 2026, ImmunityBio, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).

Will IBRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +58.5% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 48 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBRX stock forecast for 2030?

No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.

How has IBRX stock performed over the past year?

ImmunityBio, Inc. returned +179.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmunityBio, Inc. do?

ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases.

What is the latest news on IBRX?

The most recent item we track (Business Wire, 10 Aug 2026): "ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman". ImmunityBio has appointed Dr. Jim Yong Kim, former President of the World Bank and a global health leader, as Vice Chairman. He will serve in a newly created Office of the Executive Chairman, focusing on strengthening the company's international and global relationships.

Company

About ImmunityBio, Inc.

ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved interleukin-15 superagonist used in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company operates a vertically integrated model, controlling processes from discovery and research through manufacturing and commercialization via its proprietary BioShield platform, which includes cytokine fusion proteins, cell therapies, DNA vaccines, and recombinant BCG to address supply shortages. ImmunityBio maintains a robust clinical pipeline targeting solid and liquid tumors, such as non-small cell lung cancer and glioblastoma, as well as infectious diseases. Founded in 2014 and headquartered in Morrisville, North Carolina, ImmunityBio focuses on patient-centric innovations that augment natural killer cells, T-cells, macrophages, and dendritic cells for durable immune responses.

CEO Mr. Richard Gerald Adcock · 684 employees · United States · https://immunitybio.com